PWE-028 Significantly Improved Abdominal Pain (AP) with Linaclotide (LIN) vs Placebo (PBO) in Patients (PTS) with Irritable Bowel Syndrome (IBS) Regardless of Baseline Pain Severity in 2 Phase 3 Trials

Abstract

IntroductionLIN, a 14-amino-acid, minimally absorbed, guanylate cyclase C agonist (GCCA), significantly improved abdominal and bowel symptoms in 2 Phase 3 IBS with constipation (IBS-C) trials. Previous IBS trials of other...